Brown Brothers Harriman & Co. Sells 6,626 Shares of Genelux Co. (NASDAQ:GNLX)

Brown Brothers Harriman & Co. trimmed its position in Genelux Co. (NASDAQ:GNLX) by 31.4% during the 4th quarter, HoldingsChannel reports. The firm owned 14,449 shares of the company’s stock after selling 6,626 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in Genelux were worth $34,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in Genelux in the 4th quarter worth approximately $25,000. Apollon Wealth Management LLC grew its holdings in shares of Genelux by 20.4% in the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock valued at $40,000 after purchasing an additional 2,857 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Genelux in the fourth quarter worth $41,000. D.A. Davidson & CO. purchased a new stake in Genelux during the fourth quarter valued at $51,000. Finally, XTX Topco Ltd purchased a new stake in Genelux during the third quarter valued at $59,000. 37.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Genelux in a report on Monday. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Genelux presently has a consensus rating of “Buy” and a consensus target price of $18.25.

Genelux Stock Down 2.3 %

Shares of GNLX opened at $2.54 on Thursday. The business has a fifty day moving average of $4.04 and a 200 day moving average of $3.10. The company has a market cap of $88.21 million, a PE ratio of -2.67 and a beta of -1.41. Genelux Co. has a 52-week low of $1.60 and a 52-week high of $5.89.

Genelux (NASDAQ:GNLX) last released its earnings results on Friday, March 28th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.09). As a group, research analysts anticipate that Genelux Co. will post -0.88 earnings per share for the current fiscal year.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.